Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.

Vulsteke, C; Pfeil, A M; Schwenkglenks, M; Pettengell, R; Szucs, T D; Lambrechts, D; Peeters, M; van Dam, P; Dieudonné, A S; Hatse, S; Neven, P; Paridaens, R; Wildiers, H.

Breast Cancer Res Treat ; 147(3): 557-70, 2014 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-25168315

2.

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

Vulsteke, C; Lambrechts, D; Dieudonné, A; Hatse, S; Brouwers, B; van Brussel, T; Neven, P; Belmans, A; Schöffski, P; Paridaens, R; Wildiers, H.

Ann Oncol ; 24(6): 1513-25, 2013 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-23396606

3.

Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.

Wildiers, H; Dirix, L; Neven, P; Prové, A; Clement, P; Squifflet, P; Amant, F; Skacel, T; Paridaens, R.

Breast Cancer Res Treat ; 114(1): 103-12, 2009 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-18344024

4.

Estrogen conjugates and serum factors mediating the estrogenic trophic effect on MCF-7 cell growth.

Devleeschouwer, N; Legros, N; Olea-Serrano, N; Paridaens, R; Leclercq, G.

Cancer Res ; 47(22): 5883-7, 1987 Nov 15.

Artículo en Inglés | MEDLINE | ID: mdl-3664489

5.

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

Paridaens, R; Biganzoli, L; Bruning, P; Klijn, J G; Gamucci, T; Houston, S; Coleman, R; Schachter, J; Van Vreckem, A; Sylvester, R; Awada, A; Wildiers, J; Piccart, M.

J Clin Oncol ; 18(4): 724-33, 2000 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10673513

6.

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

Piccart, M J; Klijn, J; Paridaens, R; Nooij, M; Mauriac, L; Coleman, R; Bontenbal, M; Awada, A; Selleslags, J; Van Vreckem, A; Van Glabbeke, M.

J Clin Oncol ; 15(9): 3149-55, 1997 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-9294478

7.

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.

Aamdal, S; Wolff, I; Kaplan, S; Paridaens, R; Kerger, J; Schachter, J; Wanders, J; Franklin, H R; Verweij, J.

Eur J Cancer ; 30A(8): 1061-4, 1994.

Artículo en Inglés | MEDLINE | ID: mdl-7654429

8.

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.

Bruntsch, U; Heinrich, B; Kaye, S B; de Mulder, P H; van Oosterom, A; Paridaens, R; Vermorken, J B; Wanders, J; Franklin, H; Bayssas, M.

Eur J Cancer ; 30A(8): 1064-7, 1994.

Artículo en Inglés | MEDLINE | ID: mdl-7654430

9.

Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.

Kramer, J A; Curran, D; Piccart, M; de Haes, J C; Bruning, P F; Klijn, J G; Bontenbal, M; van Pottelsberghe, C; Groenvold, M; Paridaens, R.

Eur J Cancer ; 36(12): 1488-97, 2000 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-10930796

10.

Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.

Kramer, J A; Curran, D; Piccart, M; de Haes, J C; Bruning, P; Klijn, J; Van Hoorebeeck, I; Paridaens, R.

Eur J Cancer ; 36(12): 1498-506, 2000 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-10930797

11.

Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.

Paridaens, R.

Semin Oncol ; 25(5 Suppl 12): 3-6, 1998 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9865704

12.

An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.

Piccart-Gebhart, M J; Bruning, P; Gamucci, T; Klijn, J; Roy, J A; Awada, A; Kusenda, Z; Van Vreckem, A; Paridaens, R.

Semin Oncol ; 23(5 Suppl 11): 11-5, 1996 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-8893893

13.

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.

Hamilton, A; Larsimont, D; Paridaens, R; Drijkoningen, M; van de Vijver, M; Bruning, P; Hanby, A; Houston, S; Treilleux, I; Guastalla, J P; Van Vreckem, A; Sylvester, R; Piccart, M.

Clin Breast Cancer ; 1(3): 233-40; discussion 241-2, 2000 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-11899648

14.

Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.

Paridaens, R; Becquart, D; Michel, J; Vanderlinden, B; Longueville, J; Majois, F; Beauduin, M; Focan, C; Wildiers, J; Bernheim, J.

Anticancer Res ; 6(5): 1089-94, 1986.

Artículo en Inglés | MEDLINE | ID: mdl-2948441

15.

[Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)]. / Hormonothérapie et chimiothérapie adjuvante du cancer du sein.

Heuson, J C; Paridaens, R.

Rev Med Brux ; 3(4): 209-16, 1982 Apr.

Artículo en Francés | MEDLINE | ID: mdl-7046007

16.

Docetaxel is a potent cytotoxic drug in the treatment of advanced breast cancer.

Van Vaerenbergh, W; Paridaens, R; Thomas, J; Wildiers, J; Van Oosterom, A.

Acta Clin Belg ; 53(4): 264-9, 1998 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9795447

17.

Human mammary tumor growth promotion by medroxyprogesterone acetate in the tumor stem cell clonogenic assay.

Bernheim, J L; Callewaerts, W; Paridaens, R; Roobol, C.

Cancer Treat Rep ; 67(1): 101-2, 1983 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-6616491

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: